AstraZeneca (LSE: AZN) is expected to report Q4 earnings on Jan. 31. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AstraZeneca's revenues will contract -16.7% and EPS will contract -11.8%.

The average estimate for revenue is $7.21 billion. On the bottom line, the average EPS estimate is $1.42.

Revenue details
 Last quarter, AstraZeneca tallied revenue of $6.68 billion. GAAP reported sales were 19% lower than the prior-year quarter's $8.21 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $1.51. GAAP EPS of $1.21 for Q3 were 52% lower than the prior-year quarter's $2.54 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 81.1%, 70 basis points better than the prior-year quarter. Operating margin was 36.1%, 1,850 basis points worse than the prior-year quarter. Net margin was 22.8%, 1,950 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $28.05 billion. The average EPS estimate is $6.20.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 46 members out of 51 rating the stock outperform, and five members rating it underperform. Among one CAPS All-Star picks (recommendations by the highest-ranked CAPS members), one give AstraZeneca a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $46.80.

Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.